Table 1 Baseline Characteristics of the Patients.
From: Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
All evaluable patients, n = 16 | Median (range) or No.(%) |
|---|---|
Age (years) | 60 (42–73) |
Gender | |
male | 8 (50) |
female | 8 (50) |
ECOG performance status | |
1 | 8 (50) |
2 | 3 (19) |
3 | 4 (25) |
4 | 1 (6) |
Monoclonal type | |
IgG | 7 (44) |
IgA | 4 (25) |
IgM | 1 (6) |
k light chain | 3 (19) |
λ light chain | 1 (6) |
EMD | |
with EMD | 6 (38) |
solitary EMD | 3 (19) |
Complex karyotype | 1 (6) |
Cytogenetic profilesa | 9 (56) |
R-ISS stage | |
I | 3 (19) |
II | 2 (13) |
III | 11 (69) |
Time since diagnosis, months | 42 (5–96) |
MM burden at enrollment | |
Serum M protein (g/L) | 4.1 (0–63.6) |
MM cells in BM by morphology (%) | 11 (0–89) |
MM cells in BM by FCM (%) | 5.93 (0–70) |
BCMA + MM (%) | 81.12 (38.88–98.36) |
CS1 + MM (%) | 98.64 (91.58–99.14) |
Prior lines of therapies | 4 (2–8) |
Prior ASCT | 7 (44) |
Prior anti-BCMA CAR-T therapy | 2 (13) |
Prior daratumumab | 5 (31) |
Prior Selinexor | 2 (13) |
Prior proteasome inhibitors | |
Bortezomib | 16 (100) |
Carfilzomib | 1 (6) |
Ixazomib | 6 (38) |
Prior immunomodulatory drugs | |
Lenalidomide | 15 (94) |
Thalidomide | 8 (50) |
Pomalidomide | 4 (25) |
